Compare Fortive Corporation Common Stock (FTV) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortive Corporation Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Fortive Corporation Common Stock trades at $57.21 (market cap $17.54B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Fortive Corporation Common Stock is far larger — about 2.3× Spyre Therapeutics Inc. Common Stock's market cap, and Fortive Corporation Common Stock pays a 0.48% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fortive Corporation Common Stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FTV | SYRE | |
|---|---|---|
Market Cap | $17.54B | $7.52B |
Volume | 1,898,662 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $64.09 | $108.92 |
52-Week Low | $48.49 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $20.67B | $6.52B |
Dividend Yield | 0.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortive Corporation (FTV) trades at $58.07, up 1.22% today, with a neutral technical signal and a consensus analyst price target of $63.33. The stock shows strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue growth is modest, but profitability remains solid with a 12.38% net income margin. Recent news highlights product launches and a dividend increase, while institutional activity includes mixed buying and selling.
The outlook is cautiously positive, supported by raised 2026 guidance and core growth acceleration. Key risks include competitive pressures and macroeconomic headwinds. Analyst sentiment is mixed, with 36.67% buy ratings, but the stock offers potential upside to the consensus target if execution continues to improve.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fortive Corporation Common Stock
Fortive provides industrial and healthcare technology solutions. Its products and software support measurement, maintenance, worker safety, instrument sterilization, and clinical workflows.
Read more on FTV →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
